Cambridge Advisors’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $354K | Hold |
1,200
| – | – | 0.06% | 145 |
|
|
2026
Q2 | $272K | Hold |
1,200
| – | – | 0.05% | 164 |
|
|
2026
Q1 | $207K | Hold |
1,200
| – | – | 0.04% | 175 |
|
|
2025
Q4 | $239K | Buy |
+1,200
| New | +$218K | 0.05% | 166 |
|
|
2025
Q1 | – | Sell |
-1,200
| Closed | -$222K | – | 176 |
|
|
2024
Q4 | $222K | Hold |
1,200
| – | – | 0.05% | 163 |
|
|
2024
Q3 | $236K | Hold |
1,200
| – | – | 0.05% | 159 |
|
|
2024
Q2 | $248K | Hold |
1,200
| – | – | 0.06% | 157 |
|
|
2024
Q1 | $325K | Hold |
1,200
| – | – | 0.08% | 138 |
|
|
2023
Q4 | $284K | Hold |
1,200
| – | – | 0.07% | 142 |
|
|
2023
Q3 | $235K | Hold |
1,200
| – | – | 0.06% | 151 |
|
|
2023
Q2 | $252K | Hold |
1,200
| – | – | 0.06% | 147 |
|
|
2023
Q1 | $242K | Hold |
1,200
| – | – | 0.06% | 165 |
|
|
2022
Q4 | $261K | Hold |
1,200
| – | – | 0.07% | 154 |
|
|
2022
Q3 | $236K | Hold |
1,200
| – | – | 0.07% | 154 |
|
|
2022
Q2 | $257K | Hold |
1,200
| – | – | 0.07% | 157 |
|
|
2022
Q1 | $341K | Hold |
1,200
| – | – | 0.08% | 141 |
|
|
2021
Q4 | $452K | Sell |
1,200
-100
| -8% | -$38.9K | 0.1% | 130 |
|
|
2021
Q3 | $536K | Sell |
1,300
-200
| -13% | -$83.1K | 0.13% | 113 |
|
|
2021
Q2 | $555K | Hold |
1,500
| – | – | 0.13% | 107 |
|
|
2021
Q1 | $435K | Hold |
1,500
| – | – | 0.11% | 116 |
|
|
2020
Q4 | $375K | Sell |
1,500
-300
| -17% | -$71.4K | 0.1% | 119 |
|
|
2020
Q3 | $408K | Hold |
1,800
| – | – | 0.12% | 101 |
|
|
2020
Q2 | $314K | Hold |
1,800
| – | – | 0.1% | 115 |
|
|
2020
Q1 | $227K | Sell |
1,800
-200
| -10% | -$30K | 0.08% | 126 |
|
|
2019
Q4 | $306K | Hold |
2,000
| – | – | 0.09% | 121 |
|
|
2019
Q3 | $265K | Hold |
2,000
| – | – | 0.09% | 113 |
|
|
2019
Q2 | $284K | Hold |
2,000
| – | – | 0.09% | 113 |
|
|
2019
Q1 | $291K | Hold |
2,000
| – | – | 0.1% | 114 |
|
|
2018
Q4 | $226K | Hold |
2,000
| – | – | 0.08% | 122 |
|
|
2018
Q3 | $269K | Hold |
2,000
| – | – | 0.09% | 121 |
|
|
2018
Q2 | $225K | Hold |
2,000
| – | – | 0.08% | 129 |
|
|
2018
Q1 | $213K | Hold |
2,000
| – | – | 0.08% | 133 |
|
|
2017
Q4 | $219K | Hold |
2,000
| – | – | 0.08% | 128 |
|
|
2017
Q3 | $216K | Hold |
2,000
| – | – | 0.08% | 127 |
|
|
2017
Q2 | $202K | Buy |
+2,000
| New | +$184K | 0.08% | 128 |
|
Other funds holding CRL
Cambridge Advisors's CRL Position: Q3 2026 in Review
Cambridge Advisors held its Charles River Laboratories (CRL) position steady in Q3 2026 at 1,200 shares worth $354K. The position accounts for 0.06% of the portfolio, ranked #145.
Cambridge Advisors first reported a position in CRL in Q2 2017 and has held it in 35 quarters since. The position peaked at $555K in Q2 2021. 89 funds tracked by Wall St. Rank hold CRL as of Q3 2026.
- Cambridge Advisors held 1,200 shares of Charles River Laboratories worth $354K as of Q3 2026.
- Cambridge Advisors left its Charles River Laboratories share count unchanged in Q3 2026.
- Charles River Laboratories made up 0.06% of Cambridge Advisors's portfolio in Q3 2026, its #145 holding.
- Cambridge Advisors first reported a position in Charles River Laboratories in Q2 2017 and has held it in 35 quarters since.
- Cambridge Advisors's Charles River Laboratories position peaked at $555K in Q2 2021.
- 89 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.
Based on Cambridge Advisors's 13F filing for Q3 2026, filed 19 Oct 2026.